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Abstract 
Artemether and artesunate, derivatives of the antimalarial artemisinin, also exhibit antischistosomal 
properties. There is a need to assess comparatively the activity of both compounds against different 
developmental stages of schistosome parasites. Since artemisinin derivatives will be increasingly used to 
treat malaria, it is important to study the effects of ‘i-day monotherapy regimens on schistosome 
infections. We carried out experiments with mice, infected with juvenile or adult Schistosoma mansoni, 
and treated with artemether or artesunate at various doses and regimens including those currently used 
for monotherapy of malaria. Three doses of artemether, at concentrations of 150 or 300 mg/kg, 
administered to mice with juvenile S. mansoni resulted in worm reductions of 88-97%, which were 
significantly higher than the 67-77% obtained with artesunate (P < 0.05). Total concentrations of 600 
or 800 mg/kg artemether, administered over 2 or 4 consecutive days to mice with adult S. mansoni, 
reduced the worm burden significantly by 46-51% (P < 0.05). The reduction of the worm burden 
observed with artesunate was considerably lower, 24-33%, and not significant when compared with 
untreated control mice. Seven-day monotherapy regimens of artemether or artesunate given at different 
concentrations to mice with adult S. mansoni showed total worm reductions of 53-61% or 34-49%, 
respectively. We conclude that artemether and artesunate are efficacious antischistosomal agents, with 
artemether displaying consistently higher activities. Our findings may contribute to the current strategic 
discussions on the effect and use of artemisinin derivatives against schistosomes when they are used in 
malaria chemotherapy in areas of co-endemicity of both parasites. 
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Introduction 
Schistosomiasis remains an important parasitic dis- 
ease in the tropics and the mainstay of control is 
chemotherapy, with praziquantel being used as the 
drug of choice (WHO, 1999). Praziquantel is safe and 
active against all schistosome species that can infect 
humans, and generally results in high cure and egg 
reduction rates (WHO, 1993). National control pro- 
grammes in Brazil, China and Egypt have achieved 
impressive morbidity reductions, mainly due to large- 
scale chemotherapy campaigns (CHITSULO et al., 
2000). In recent years, the price of praziquantel has 
dropped substantially. By the end of 1999, the average 
cost of a single treatment was US$ 0.40 (CIOLI, 2000), 
and the co& have decreased further over the past ‘2 
vears (APPLETON & MBAYE. 2001: WHO. 2001). This 
low cost will further encourage’ widespread use of 
praziquantel and treatment is being proposed by new 
initiatives targeting praziquantel to school-aged chil- 
dren. 
Evidence from laboratory studies and field trials 
has been accumulated with schistosomes exhibiting a 
somewhat decreased susceptibility to praziquantel 
(FALLON & DOENHOFF, 1994; ISMAIL et al, 1996, 
i999; GEERTS & GRYSEELS, 2000; WILLIA& et al.; 
2001: DANSO-APPIAH & DE VLAS. 2002). Althouah 
these’observations are not of any clinical significance io 
far, they indicate the importance of closely monitoring 
the efficacy of praziquantel in different epidemiological 
settings, and stress the need for research and develop- 
ment of novel antischistosomal drugs (CIOLI, 1998, 
2000; GEERTS & GRYSEELS, 2000; GRYSEELS et al., 
2001). 
Chinese scientists have discovered that derivatives of 
artemisinin, which are already widely and effectively 
used in the treatment of malaria (MCINTOSH & 
OLLIARO, 200 l), also display antischistosomal proper- 
ties. Detailed in-vivo studies with Schistosomajaponicum 
revealed that the juvenile stages of the parasite were 
highly susceptible to artemether (XIAO et al, 1995, 
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1998) and artesunate (LI et al., 1996). Both drugs also 
showed activity against adult S. japonicum, but-worm 
burden reductions were significantlv lower. These flnd- 
ings were confirmed in subsequent randomized con- 
trolled trials, as artemether and artesunate reduced the 
incidence of patent S. japonicum infections by 60- 
100% (LI et al, 1996; XI.40 et al, 2000a). In recent 
years, experimental work and clinical trials have been 
extended from S. japonicum to S. mansoni and S. 
haematobium (for review see UTZINGER et al., 2001a). 
Artemether proved highly active against juvenile 
S. mansoni (CIAO et al., 2000b) and S. haematobium 
(XIAO et al., 2000~). A randomized, controlled trial 
showed a prophylactic efficacy of artemether of 50% 
against reinfection with S. mansoni (UTZINGER et al., 
2000). Although the susceptibility of different develop- 
mental stages of S. mansoni to artesunate has yet to be 
investigated, recent studies confirm that artesunate is 
active against S. mansoni. Administration to infected 
patients on 5 consecutive days resulted in parasitologi- 
cal cure rates of 40-54%, when evaluated 10 or 24 
weeks post-treatment (DE CLERCQ et aZ., 2QOOa, 
2000b). The first results from 2 field studies indicate 
that artesunate also shows an effect against S. haema- 
tobium, but the therapeutic efficacy is somewhat lower 
than against S. mansoni (BORRMANN et al., 2001; DE 
CLERCQ et al, 2002). 
In the present study, we assessed comparatively the 
effects of different doses and treatment regimens 
of artemether and artesunate on juvenile and adult 
S. mansoni in exnerimentallv infected mice. We also 
administered the 2 drugs fo mice harbouring adult 
worms, following the recommended malaria mono- 
therapy regimens. These data will be of importance for 
subsequent clinical trials in humans and will contribute 
to more rational discussions about the potential of 
artemisinins in the control of schistosomiasis. 
Materials and Methods 
Ethical clearance, parasites, drugs and mice 
Ethical clearance for the animal studies presented 
here was obtained from the local government based on 
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Swiss national regulations. All experiments were car- 
ried out in the laboratories of the Swiss Tropical 
Institute. 
Cercariae of S. mansoni (Liberian strain) were ob- 
tained from infected BiomphaZaria gZabrata snails, fol- 
lowing routine procedures at our laboratories. 
Artesunate was obtained from Meuha AG (Aesch, 
Switzerland) and artemether was provided by the 
Kunming Pharmaceutical Corporation (Kunming, 
China; lot No. 97080). Both pharmaceutical com- 
panies documented that their products showed very 
high purity: 99.4% in the case of artesunate and 99.6% 
for artemether. For intragastric administration, drugs 
were suspended in 7% Tween-80 and 3% ethanol. 
A total of 165 female MORO strain mice, weighing 
18-22 g, were purchased from Biotechnology and Ani- 
mal Breeding Division (Fiillinsdorf, Switzerland). The 
animals were maintained on Rodent Blox, obtained 
from Eberle NAFAG (Gossau, Switzerland), and water 
ad libitum. 
Infection and treatment 
Mice were each infected subcutaneously with 80 
S. mansoni cercariae. Two groups of 10 mice served as 
control, therefore they remained untreated. 
In the first series of experiments, 4 groups of 10 mice 
were treated intragastrically with 3 doses of artesunate 
or artemether at a lower concentration of 150 mg/kg or 
a higher one at 300 mg/kg. The first 2 doses were 
administered 7 and 21 days after infection, when the 
mice harboured juvenile S. mansoni. These treatments 
were followed by a final dose at the same concentration, 
35 days post-infection. 
The second set of experiments was done with mice 
that harboured adult S. mansoni worms. Ten groups of 
5 mice were treated intragastrically with artesunate or 
artemether at different doses and treatment regimens. 
The first 2 groups received 100 mg/kg artesunate or 
artemether for 6 consecutive days, with the first 
dose administered 46 days after infection. The next 4 
groups were treated on 4 consecutive days with 150 or 
200 mg/kg artesunate or artemether, starting also at 
day 46’poit-infection. The last 4 groups were treated 
twice. on dav 46 and 47 after infection, with dailv doses 
of artksunate or artemether at 300 or do0 mg/kg: 
The third series of experiments also focused on adult 
S. mansoni. In this case, the treatment regimen followed 
that recommended bv the World Health Organization 
for malaria monotherapy with artemisinini (WHO, 
1998: MCINTOSH & OLLIARO. 2001). Form-six davs 
after infection, 6 groups of 5 &ice w&e treited intra- 
gastrically with artesunate or artemether at an initial 
dose of 200, 300 or 400 mg/kg. Mice were re-treated 
on 6 consecutive days by the same route of administra- 
tion, but using half of the initial dose. Therefore, the 
different treatment groups received total doses of 800, 
1200 or 1600 mg/kg. Finally, 5 groups of 5 mice 
were treated with a high single dose of artesunate (800 
and 1200mg/kg) or artemether (800, 1200 and 
1600 mg/kg). 
Dissection of mice and assessment of the effect of artesunate 
or artemether 
In the first 2 series of experiments, one group of 10 
infected but untreated mice served as control, and was 
sacrificed by blood-letting 60 days after infection. All 
mice in the different treatment groups were also sacri- 
ficed by blood-letting, 27 or 28 days after the final drug 
administration. A second group of 10 infected but 
untreated mice served as control in the third set 
of experiments. They were sacrificed 75 days post- 
infection. Mice from the different treatment groups 
were sacrificed between 24 and 31 davs after the final 
medication. 
All mice were dissected and the liver and small and 
large intestines were removed. The liver was placed 
into a 20 X 20-cm transparent plastic folder and gently 
compressed between 2 glass plates, so that the paren- 
chyma became a flat and evenly dispersed layer. The 
layer was placed under a stereoscopic microscope and 
examined at X 10 magnification by one experienced 
microscopist. This procedure allowed the sexing and 
counting of all S. mansoni worms. The small and large 
intestines were placed in a Petri dish and all the 
mesenteric veins were examined under a stereoscopic 
microscope, also at X 10 magnification, by the same 
microscopist. All S. mansoni worms in the mesenteric 
veins were removed, sexed and counted. 
In a first step, we assessed the effect of a treatment 
with artesunate or artemether, following the various 
doses and regimens, by comparing the mean number of 
total (and female) worms in any treatment group with 
that of the corresponding control group. In a second 
step, we compared the mean number of total (and 
female) worms in the different artesunate treatment 
groups with that of the corresponding artemether 
groups. For statistical analysis, we used Student’s t-test, 
allowing for unequal variance. 
Results 
Effect of artesunate or artemether on juvenile S. mansoni 
In the first series of experiments, mice previously 
infected with 80 S. mansoni cercariae received the first 
dose of 150 or 300 mg/kg artesunate or artemether 7 
days after infection, when schistosomula have normally 
reached the lung. Two further doses at the same 
concentrations were administered 14 and 28 days later, 
when parasites usually have developed into organogeny 
and oviposition stages, respectively. Administration of 
artesunate or artemether at these doses and treatment 
regimen resulted in total and female worm reductions 
between 67% and 99% (Table 1, groups 2-5). The 
reductions in the total and female worm burden were 
highly significant, as compared to the untreated control 
group (P < 0.001). Total and female worm reductions 
were significantly greater following the administration 
Table 1. Mice infected with juvenile Schistosoma mansoni and treated three times with artemether or 
artesunate at two different doses (n = number of mice) 
Female 
Total worm Mean female worm 
Administration: Mean total burden worm burden 
Dose day after Mice worm burden reduction burden reduction 
Group Treatment (mg/kg) infection (n) (SD) (%I (SD) (%I 
1 Control 
lS0 2 Artesunate 7,21,35 
3 Artesunate 300 7,21,35 
: Artemether 300 150 7,21,35 7,21,35 
“Group 4 tested verux group 2 (*P < 0.05). 
bGroup 5 tested versus group 3 (**P < 0,001). 
10 19.7 (7.4) - 8.7 (3.2) 
10 6.5 (5.5) 67 2.6 (2.6) 70 
4.5 (2.1) 77 2.2 (1.3) 75 t: 
10 2.4 0.6 (1.6)“” l.O)b** 97 88 0.1 0.8 (0.6)a 3 b** 
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of 300 mg/kg artemether rather than 150 mg/kg. In 
contrast, doubling the dose of artesunate from 150 to 
300 mg/kg did not result in significantly higher total 
and female worm burden reductions. 
Treatment with artemether showed consistently 
higher activities against juvenile S. mansoni than arte- 
sunate. At the higher dose of 300 mg/kg, the dif- 
ferences in the total and female worm burdens were 
highly significant (P < 0.001). At the lower dose of 
150 mg/kg, artemether also showed a significantly 
higher reduction of the total worm burden when com- 
pared to artesunate (P = 0.045), while the difference 
in the mean female worm burden showed borderline 
significance (P = 0,059). 
Effect of artesunate or artemether on adult S. mansoni 
In the second set of experiments, mice infected with 
adult S. mansoni were treated with artesunate or arte- 
mether at various doses and regimens. Administration 
of artesunate or artemether at 100 mg/kg on 6 con- 
secutive days, or 150 mg/kg on 4 consecutive days 
resulted in total worm reductions of 15529%, which 
were not significant when compared to the group of 
untreated control mice (Table 2, groups 6, 7, 11, 12). 
Higher artemether concentrations of 200, 300 or 
400 mg/kg, administered on 2 or 4 consecutive davs 
(groups’ 13- 15), revealed total worm reductions of 46- 
53%. which were significant when comuared to the 
untreated control group (P < 0.05). However, admin- 
istration of artesunate at the same concentrations and 
regimens had no significant impact on the total worm 
burden (groups S-10). In all different treatment 
groups, female worm reductions were consistently 
higher than the total worm reductions, resulting always 
in significantly lower female worm burdens when com- 
aared to the corresuondine control (P < 0.05). Highest 
iemale worm reductions, 79-86%, were observed khen 
artemether was administered twice, at daily doses of 
300 or 400 mg/kg, or on 4 consecutive days at a daily 
dose of 200 mg/kg (P < 0.001). 
Although repeated doses of artemether to adult 
S. mansoni, especially at daily doses of a200 mg/kg, 
showed consistently higher total and female worm 
reductions than obtained with artesunate, these differ- 
ences were not statistically significant. 
Effect of a Pday monotherapy with artemisinins on adult 
S. mansoni 
In the third series of experiments, a first initial dose 
of artesunate or artemether, at 200, 300 or 400 mg/kg, 
was administered to mice that harboured 46-day-old 
adult S. mansoni and was followed by 6 doses over 
consecutive days at half of the initial concentrations. 
This regimen, which is the one recommended for 
malaria monotherapy using artemisinins, resulted in 
total worm reductions of 34-49% in the case of arte- 
sunate (Table 3, grouns 17-19). and 53-61% when 
using artemether (groups 22-24 j.- With the only excep- 
tion of a 7-day monotherapy with artesunate at the 
highest concentration (group 19), the reductions in the 
total worm burden were significant when compared to 
the untreated control group (P < 0.05). In all different 
treatment groups, female worm reductions were consis- 
tently higher than total worm reductions, and were all 
highly significant when compared to the corresponding 
control group. Seven-day monotherapy with arte- 
mether, at all different dose levels tested, reduced the 
female worm burden by 78-83% (P < 0.001). 
Comparison of the total and female worm reductions 
obtained by a 7-day monotherapy using artemether or 
artesunate revealed artemether being consistently more 
effective; however, the differences were statistically not 
significant. It should be noted that 2 mice died in 2 of 
the 6 treatment groups: (1) artemether: 1 X 300 mg/kg 
plus 6 X 150 mg/kg (group 23); and (2) artesunate: 
1 X 400 mg/kg plus 6 X 200 mg/kg (group 19). 
Finally, artesunate or artemether was administered 
to adult S. mansoni at single high doses. Four out 
of 5 mice died when artesunate was administered at 
800 mg/kg (group 20) and all 5 mice were killed by a 
single dose of 1200 mg/kg (group 21). Mice tolerated 
higher doses of artemether; however, 2 out of 5 mice 
died when a single dose of 1200 mg/kg was admin- 
istered (group 26). 
Discussion 
The results of our in-vivo studies clearly showed that 
artemether and artesunate are highly active against the 
juvenile stages of S. mansoni, whereas adult worms are 
considerably less susceptible. The similarities in sus- 
ceptibility of different developmental stages of S. man- 
soni to artemether and artesunate might be explained 
by the fact that the 2 compounds are remarkably re- 
lated in terms of chemical structures and also pharma- 
codynamic properties (ZIFFER et al., 1997; LI et al., 
1998; VROMAN et al., 1999). In this connection, it 
could be speculated that other artemisinin derivatives 
should exhibit similar antischistosomal properties, 
which has indeed been confirmed in viva for arteether 
(XIAO et aZ., 1992) and also dihydroartemisinin (ABDEL 
AZIZ & EL-BADAWY, 2000). 
Artemether showed consistently higher antischistoso- 
ma1 activities than artesunate. Differences in the meta- 
bolic pathways of the 2 compounds might account for 
Table 2. Mice infected with adult Schistosoma mansoni and treated with artemether or artesunate at 
different doses and treatment regimens (n = number of mice) 
Female 
Total worm Mean female worm 
Administration: Mean total burden worm burden 
Dose day after Mice worm burden reduction burden reduction 
Group Treatment (mg/kg) infection (n) (SD) (%) (SD) W) 
1 Control - 10 19.7 (7.4) 8.7 (3.2) 
6 Artesunate 100 46,47,48,49,50,51 5 14.8 (3.9)” 25 5.2 (1.6)“* 4; 
7 Artesunate 150 46, 47, 48, 49 5 15.6 (5.1)” 21 5.2 (1.6)“” 40 
; Artesunate 200 300 46, 47 47,48, 49 : 14.2 15.0 (6.3)” (1.9)“” 8 28 4 3.8 4.2 3 6 * 56 2 
10 Artesunate 400 46,47 5 13.2 (5.2)” 33 4.0 (2.8)a* 54 
:.: Artemether 100 150 46,47,48,49, 50, 51 5 (6.6)” 15 (0.8)a*  16.8 14.0 4 7 5.2 4.4 1 5 “ 40 9 
13 Artemether 200 46, 47, 48,49 z 9.2 (l.l)“* 2 1.6 (0.9)‘** 82 
14 Artemether 300 46,47 5 10.6 (4.9)“* 46 1.8 (,.,)a** 79 
15 Artemether 400 46,47 5 9.6 (2.3)“* 51 1.2 (,.I),** 86 
“Groups 6-15 testedversusgroup 1 (*P < 0.05; **P < 0.001). 
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this finding. Previous studies assessing the biotrans- 
formation in rats revealed that artesunate had an ex- 
tremely short terminal half-life of only 2-4 min and 
was converted rapidly into its major active metabolite 
dihydroartemisinin (MAGGS et al., 2000; DAVIS et aZ., 
200 1). In contrast, pharmacokinetic studies showed 
that artemether has a considerable longer terminal half- 
life of l-2 h and is converted more slowly into di- 
hydroartemisinin and to a smaller extent also into 
several hydroxylated metabolites (VAN AGTMAEL et al., 
1999; MAGGS et aZ., 2000). Therefore, it is possible 
that not only the mother compounds artemether and 
artesunate, but also metabolites could play an impor- 
tant role in explaining the differences in antischisto- 
somal properties. 
Our findings are in agreement with previous studies 
assessing the susceptibility of different developmental 
stages of S. rnansoni to artemether. Large worm reduc- 
tions of 56-90% were observed when a single dose of 
300 or 400 mg/kg artemether was administered to mice 
infected with 7-28-day-old schistosomula, whereas 
drug administration to adult S. mansoni resulted in 
considerably lower worm reductions of 30-5 1% O(IA0 
& CATTO, 1989; XIAO et al., 2000b). Artemether, 
given at a single dose of 15 mg/kg to rabbits infected 
with 5-21-day-old S. japonicum, also proved highly 
active, with worm reductions of 69-93%. The effect of 
a single dose administered to adult S. japonicum was 
still marked, but worm reductions were significantly 
lower (XIAO et aZ., 1995). In the first series of in-vivo 
studies with juvenile S. haematobium harboured in ham- 
sters, the schistosomicidal activity of artemether was 
also confirmed (CIAO et al., 2000~). These experimen- 
tal findings have been confirmed in a series of rando- 
mized controlled trials against S. japonicum (XIAO et 
aZ., 2000a), which is considered as one of the most 
important contributions to schistosomiasis control in 
China in recent years (YUAN et aZ., 2000). Following a 
successful field trial against S. mansoni (UTZINGER 
et aZ., 2000), the relevance for areas endemic for 
S. mansoni and S. haematobium is currently being dis- 
cussed (UTZINGER et al., 200 1 a). 
Although detailed studies on the susceptibility of 
S. mansoni parasites of different ages to artesunate have 
yet to be conducted, it is likely that schistosomula are 
more susceptible than adult worms. In fact, first in-vivo 
studies with adult S. mansoni harboured in mice and 
treated once or repeatedly with artesunate at 300 or 
500 mg/kg only resulted in small numbers of dead 
worms (ARA~JJO et al., 1999). These experiments 
should be repeated with juvenile S. mansoni and are 
expected to result in large worm reductions, as has 
already been observed after administration of arte- 
sunate to juvenile S. japonicum in different host animals 
(LI et aZ., 1996). First studies in human populations 
have confirmed that artesunate is safe and effective in 
the prevention of S. japonicum infections (LI et al., 
1996), as well as in the cure of S. mansoni infections 
(DE CLERCQ et al., 2000a, 2000b). Although therapeu- 
tic efficacy of artesunate against S. haematobium was 
considerably lower than against S. mansoni, the infec- 
tion intensities and the proportion of heavy infections 
decreased significantly (BORRMANN et aZ., 2001; DE 
CLERCQ et aZ., 2002). 
The observation that artemisinin derivatives show 
highest activities on early developmental stages of schis- 
tosome parasites is quite interesting per se, because this 
is exactly the time when praziquantel is ineffective 
(ANDREWS, 1981; SABAH et aZ., 1986). Consequently, 
a combined treatment with praziquantel together with 
an artemisinin derivative has been proposed, as this 
covers the whole period of the parasite in its vertebrate 
~~~~(UTZINGER etal. ,2001a).Recentlaboratory stud- 
ies with S. japonicum and S. mansoni parasites of differ- 
ent ages confirmed that a combination therapy with 
praziquantel and artemether showed significantly larger 
flRG UTZINGER ETAL. 
worm reductions than each drug administered singly 
(XIAO et al., 2000d; UTZINGER et aZ., 2001b). In 
addition, first clinical observations among S. mansoni- 
infected patients in Senegal also report an additive 
effect by combining praziquantel with artesunate, when 
assessing parasitological cure rates 5 weeks post-treat- 
ment (DE CLERCQ et al., 2000b). In a recent study 
done in Gabon, combination therapy with praziquantel 
and artesunate resulted in significantly higher egg re- 
duction rates than praziquantel administration alone 
(BORRMANN et al., 200 1). 
More important is the finding that 7-day artemisinin 
monotherapy regimens, recommended for patients with 
intolerance to alternative antimalarial drugs (WHO, 
1998; MCINTOSH & OLLIARO, 2001), have a signifi- 
cant effect on S. mansoni. This result is of great signifi- 
cance, since artemisinins are increasingly used in 
the treatment of severe and uncomplicated malaria, 
especially in areas where parasites have developed resis- 
tance to nearly all currently available antimalarials 
(PRICE et aZ., 1998, 1999). Therefore, we suggest that 
in areas where malaria and schistosomiasis are co- 
endemic and artemisinins will be used in the treatment 
of malaria-in monotherapy or in combination with 
other antimalarial drugs (WHITE, 1999)-the impact 
on the prevalence and intensity of schistosome infec- 
tions should be monitored and evaluated, as recently 
stressed at a WHO-TDR (2001) meeting about the 
potential of artemisinins in the prevention and control 
of schistosomiasis. 
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Abstract 
A graduated pole for height measurement, esti- 
mating the number of praziquantel tablets 
needed for treatment, was field-tested on 1289 
children in Zanzibar. A bathroom-type scale per- 
formed better than the dose pole in delivering the 
optimal dose (40-60 mg/kg) and the 2 methods 
performed similarly in delivering a dose consid- 
ered appropriate (30-60 mg/kg). 
Keywords: schistosomiasis, Schistosoma spp., chemo- 
therapy, praziquantel, dosage determination, ‘dose 
pole’, Zanzibar 
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Introduction 
The World Health Organization (WHO) advocates 
the control of schistosomiasis by regular treatment of 
vulnerable groups with praziquantel, delivered through 
schools and health services. One of the major disadvan- 
tages of wide delivery of praziquantel is the fact that its 
dosage has to be calculated according to weight. HALL 
et al. (1999), recognizing that the provision of sufficient 
weighing scales to maintain long-term mass dosing 
programmes in the rural areas of developing countries 
was a major problem, proposed the use of a graduated 
pole to assess height and so determine the number of 
tablets of praziquantel to be used for each individual. A 
‘dose pole’ was tested on height and weight data of 
more than 25 000 children from 10 countries with posi- 
tive results (MONTRBSOR et al., 2001). The aim of our 
study was to field-test the dose pole in Zanzibar and 
compare its performance with the that of a bathroom- 
type scale. A digital scale was used as a reference 
standard. 
Material and Methods 
A wooden pole was locally produced, with thresh- 
olds and corresponding dosages as described by 
MONTRESOR et al. (2001): 110-125 cm = 1.5 tablets, 
125-138 cm = 2 tablets, 138-150 cm = 25 tablets, 150- 
160 cm = 3 tablets and 160-178 cm = 4 tablets. 
The cost of producing the wooden dose pole and that 
of purchasing a new scale was similar, approximately 
US$6. The field test was conducted in April 2001 on 
1289 children in Kinyasini School, Zanzibar, United 
Republic of Tanzania. Each child received 3 inde- 
pendent evaluations of the number of tablets of prazi- 
quantel needed for treatment: the first (the reference 
standard) using a digital scale (Seca Inc., Columbia, 
Maryland, USA), the second using a new bathroom- 
type scale (Camry Inc., China), and the third using the 
dose pole. 
The results were recorded separately so that the 
